Evidence map›Paper›PMID 35768874›Full record

ArticleOrphanet journal of rare diseases2022

Cardiac involvement in MPS patients: incidence and response to therapy in an Italian multicentre study.

Simona Sestito, Giada Rinninella, Angelica Rampazzo, Francesca D'Avanzo, Lucia Zampini, Lucia Santoro, Orazio Gabrielli, Agata Fiumara, Rita Barone, Nicola Volpi and 3 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Natural History of Morquio A Syndrome.Journal of inherited metabolic disease · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Simona SestitoPediatric Unit, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
Giada RinninellaPediatric Unit, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.
Angelica RampazzoLaboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health, University of Padova, Padua, Italy.
Francesca D'AvanzoLaboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health, University of Padova, Padua, Italy.
Lucia ZampiniDivision of Pediatrics, Department of Clinical Sciences, Ospedali Riuniti, Presidio Salesi, Polytechnic University of Marche, Ancona, Italy.
Lucia SantoroDivision of Pediatrics, Department of Clinical Sciences, Ospedali Riuniti, Presidio Salesi, Polytechnic University of Marche, Ancona, Italy.
Orazio GabrielliDivision of Pediatrics, Department of Clinical Sciences, Ospedali Riuniti, Presidio Salesi, Polytechnic University of Marche, Ancona, Italy.
Agata FiumaraDepartment of Clinical and Experimental Medicine, Child Neurology and Psychiatry, University of Catania, Catania, Italy.
Rita BaroneDepartment of Clinical and Experimental Medicine, Child Neurology and Psychiatry, University of Catania, Catania, Italy.
Nicola VolpiDepartment of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Maurizio ScarpaLaboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health, University of Padova, Padua, Italy.
Rosella TomaninLaboratory of Diagnosis and Therapy of Lysosomal Disorders, Department of Women's and Children's Health, University of Padova, Padua, Italy.
Daniela ConcolinoPediatric Unit, Department of Science of Health, Magna Graecia University, Catanzaro, Italy. dconcolino@unicz.it.ORCID 0000-0003-1223-7358
Magna Graecia University · ITUniversity of Padua · ITUniversity of Catania · ITUniversity of Modena and Reggio Emilia · ITUniversity of Udine · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucopolysaccharidoses (MPSs) are a group of lysosomal storage disorders caused by the deficit of lysosomal hydrolases involved in the degradation of glycosaminoglycans (GAGs). The course is chronic and progressive, with multisystemic involvement that often leads to cardiovascular disease. We describe the overall incidence and type of cardiac damage in a cohort of Italian MPS patients, and their progression over time, also with reference to treatment efficacy in patients under Enzyme Replacement Therapy (ERT). Moreover, we report a possible association between genetic variants and cardiac phenotype in homozygous and hemizygous patients to understand whether a more aggressive clinical phenotype would predict a greater cardiac damage.

resultsOur findings confirm that cardiac involvement is very common, already at diagnosis, in MPS VI (85.7% of our cohort), and in MPS II (68% of our cohort) followed by MPS I subjects (55% of our cohort). The most frequent heart defect observed in each MPS and at any time-point of evaluation was mitral insufficiency; 37% of our patients had mitral insufficiency already at diagnosis, and 60% at post-ERT follow-up. After at least six years of treatment, we observed in some cases (including 6 MPS II, 2 MPS IV and 2 MPS VI) a total regression or improvement of some signs of the cardiac pathology, including some valve defects, though excluding aortic insufficiency, the only valvulopathy for which no regression was found despite ERT. The general clinical phenotype proved not to be strictly correlated with the cardiac one, in fact in some cases patients with an attenuated phenotype developed more severe heart damage than patients with severe phenotype.

conclusionsIn conclusion, our analysis confirms the wide presence of cardiopathies, at different extent, in the MPS population. Since cardiac pathology is the main cause of death in many MPS subtypes, it is necessary to raise awareness among cardiologists about early cardiac morpho-structural abnormalities. The encouraging data regarding the long-term effects of ERT, also on heart damage, underlines the importance of an early diagnosis and timely start of ERT.

Indexed as

Heart InjuriesMitral Valve InsufficiencyMucopolysaccharidosesMucopolysaccharidosis IIMucopolysaccharidosis VIEnzyme Replacement TherapyHumansIncidenceEnzyme replacement therapy (ERT)Glycosaminoglycans (GAGs)Heart involvementMucopolysaccharidoses (MPS)Valvulopathies

Identifiers

PMID35768874
PMCPMC9245260
OpenAlexW4283752473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.